FEMASYS INC. - COMMON

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

12 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys to Exhibit at the Annual AAGL 2024 Global Conference

07 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

01 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed

30 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

10 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

02 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Announces Infertility Clinic Customers from Coast to Coast

18 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

11 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

05 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

29 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

27 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

27 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

20 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

17 May 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

16 May 2024 07:30:00 By Nasdaq GlobeNewswire

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

09 May 2024 07:30:00 By Nasdaq GlobeNewswire